Who Researches This?
Who Researches SS-31?
SS-31 is researched by people focused on anti-aging at the cellular level — specifically mitochondrial health. If you're interested in longevity science and targeting the root cause of age-related decline (mitochondrial dysfunction) rather than just symptoms, SS-31 is one of the most targeted tools in this space. It's also being studied for heart, kidney, and muscle conditions linked to mitochondrial failure. It complements NAD+ and epitalon in anti-aging stacks.
Related Resources
- Stacks: Anti-Aging Stack
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
What Is SS-31?
SS-31 belongs to the Szeto-Schiller (SS) peptide class — aromatic-cationic peptides that selectively accumulate in mitochondria independent of mitochondrial membrane potential. This selectivity is remarkable: SS-31 concentrates ~5,000-fold in the inner mitochondrial membrane compared to cytoplasmic concentrations.
The clinical development of SS-31 (as elamipretide) has advanced furthest among mitochondria-targeted therapies. Stealth BioTherapeutics (now Larimar Therapeutics) conducted clinical trials for multiple indications related to mitochondrial dysfunction, and the compound received both Breakthrough Therapy and Fast Track designations from the FDA for Barth syndrome (a rare genetic mitochondrial disease).
Mechanism of Action
- Cardiolipin stabilization: SS-31 binds to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane. Cardiolipin is essential for the structural organization and function of electron transport chain complexes. Age and disease cause cardiolipin peroxidation and dysfunction.
- Electron transport optimization: By stabilizing cardiolipin, SS-31 optimizes electron transfer between respiratory complexes, improving ATP production efficiency
- ROS reduction: Improved electron transport reduces electron leakage and superoxide production — reducing oxidative stress at its source
- Mitochondrial bioenergetics: Restores mitochondrial membrane potential and ATP synthesis capacity in dysfunctional mitochondria
Researching peptides? We did the hard part.
Get our free Peptide Starter Kit — the 5 most researched compounds, simplified into one actionable guide.
No spam · Unsubscribe anytime
Clinical Evidence
- Barth syndrome: FDA Breakthrough Therapy designation. Phase 2/3 trials showed improvements in the 6-minute walk test and cardiac function in Barth syndrome patients
- Heart failure: Phase 2 trials (EMBRACE) in patients with heart failure showed improvements in left ventricular volumes, though primary endpoints in larger trials were mixed
- Primary mitochondrial myopathy: Improvements in exercise tolerance and fatigue scores
- Age-related macular degeneration: Phase 1/2 trials explored subcutaneous elamipretide for geographic atrophy
Dosage Overview
Clinical trial dosing:
- Subcutaneous: 40 mg daily (clinical trial dose for Barth syndrome)
- IV (acute settings): 0.05 mg/kg/hour infusion (heart failure trials)
- Research: 0.5–5 mg subcutaneous (extrapolated from animal studies)
Use the peptide calculator for reconstitution of research-grade material.
Side Effects & Safety
- Injection site reactions: Most common adverse event in clinical trials
- Generally well-tolerated across multiple clinical trials
- No significant cardiac safety signals in heart failure patients (an important finding given the cardiac indication)
- Mild headache reported in some trial participants